1.2 Registration, Fees and Candidate Decisions

Registration, Fees and Candidate Decisions

These totals include application and examination fees. The June 2026 handbook separates early-bird member fees into $135 application plus $300 exam; regular member fees are $135 plus $325. Nonmember early-bird fees are $135 plus $350, and regular fees are $200 plus $400. There is no additional universal $50 late-registration surcharge in this schedule.

Spring testing runs February 15–May 15 and fall testing July 15–October 15. The current page lists spring early-bird registration October 20–December 31 and regular registration January 1–April 30; fall early-bird registration May 20–July 15 and regular registration July 16–September 30. These are programme windows, not a guarantee of an available PSI appointment. Schedule after receiving eligibility confirmation.

The June 2026 handbook permits retesting 60 days after the original appointment or in the next available testing window, subject to eligibility and scheduling. An eligible immediate retest requires the examination fee rather than the initial full application total: member $300–$325 or nonmember $350–$400 under that fee table.

After two unsuccessful attempts, or expiry of the one-year application eligibility, a new application and current fees are required. Consult ACRP if window and waiting-period wording leaves your particular appointment uncertain.

Credential maintenance is biennial. Use ACRP's current maintenance handbook for its continuing education, professional activity and fee rules; passing once does not create lifetime certification. ACRP does not publish a universal raw passing percentage or a first-attempt pass rate in the current sources checked here. Budget study time from your own ECO diagnostic results rather than an unsupported pass-rate prediction.

Critical Candidate Misconceptions & Testing Traps

To pass the CCRA examination on the first attempt, candidates must anticipate common psychometric traps and discard flawed assumptions:

Trap 1: The "Raw Percentage" Calculation

Many candidates believe they need a 70% or 75% raw score to pass. When encountering several difficult questions early in the exam, anxiety spikes, leading to rushed decisions. In reality, the scaled 600 cut score accounts for form difficulty. If a test form contains unusually complex scenario items, the psychometric scaling adjusts accordingly. Remain calm and focus on each question individually.

Trap 2: The "Pretest Detection" Game

Candidates sometimes try to outsmart the exam by identifying and guessing on questions they assume are unscored pretest items. Pretest items are selected from the same item-writing workshops as active items and cover the identical six domains. Devoting time to guessing which items are experimental wastes critical cognitive energy and frequently leads candidates to blow past scored questions.

Trap 3: The "Local Regulation" Reflex

Questions often present realistic clinical scenarios involving investigational new drug applications or institutional review boards. A US candidate might instinctively look for FDA Form 1572, financial disclosure 21 CFR 54, or HIPAA authorizations. Unless explicitly noted, the examination reference framework is rooted in ICH GCP terminology (e.g., "Investigator Agreement", "Ethics Committee Approval", "Subject Confidentiality Protections").

Trap 4: The "Overreaching CRA" Fallacy

In practice, experienced CRAs often develop close working relationships with site coordinators and may be tempted to "fix" errors directly—such as filling in missing CRF fields, making corrections in patient medical charts, or telling an investigator how to treat an adverse event. In the monitoring role, avoid ad hoc performance of site clinical duties, medical decisions or unsupported corrections. Follow documented authority and preserve investigator responsibility. R3 permits sponsor changes to investigator-entered data only when justified, agreed in advance by the investigator and documented; that controlled arrangement does not authorise impersonation or informal edits to meet a deadline. The CRA monitors, verifies, and reports; the Principal Investigator retains total clinical and site authority.

Trap 5: The "Passive Observer" Fallacy

Conversely, some candidates assume that because the CRA is an external monitor, they should take no action when discovering severe non-compliance. In situations where human subject safety is compromised (such as an unapproved protocol amendment altering drug dosing or an unreported life-threatening SAE), the monitor must not merely leave an action item for the next routine visit. The monitor must immediately alert the Principal Investigator and escalate the issue to the sponsor's medical monitor or project manager.

The Clinical Research Associate Role & Exam Preparation Framework

Clinical trials are highly complex, multi-site human endeavors fraught with logistical, clinical, and ethical risks. While the trial sponsor designs the protocol, provides investigational products, and submits clinical study reports to regulatory authorities, the sponsor relies on the Clinical Research Associate (CRA)—traditionally termed the study monitor—to verify that trial execution at the investigative site mirrors the study protocol and adheres to all applicable standards.

The monitor is neither an administrative clerk nor a medical auditor; the monitor is the proactive guardian of human subject safety, regulatory compliance, and scientific validity in the field.

Official sources

Checked October 18, 2026: ACRP CCRA programme, ACRP Initial Certification Handbook, June 2026, ACRP CCRA Exam Content Outline.